Faculty Collaboration Database

A phase 2 study of bortezomib in combination with ifosfamide/vinorelbine in paediatric patients and young adults with refractory/recurrent Hodgkin lymphoma: a Children's Oncology Group study. Br J Haematol 2015 Jul;170(1):118-22

Date

04/03/2015

Pubmed ID

25833390

Pubmed Central ID

PMC4478135

DOI

10.1111/bjh.13388

Scopus ID

2-s2.0-84931563104 (requires institutional sign-in at Scopus site)   22 Citations

Abstract

A Children's Oncology Group clinical trial aimed to determine if bortezomib (B) increased the efficacy of ifosfamide and vinorelbine (IV) in paediatric Hodgkin lymphoma (HL). This study enrolled 26 relapsed HL patients (<30 years) treated with two to four cycles of IVB. The primary endpoint was anatomic complete response (CR) after two cycles. Secondary endpoints included overall response (OR: CR + partial response) at study completion compared to historical controls [72%; 95% confidence interval (CI): 59-83%]. Although few patients achieved the primary objective, OR with IVB improved to 83% (95% CI: 61-95%; p = 0.32). Although not statistically different, results suggest IVB may be a promising combination.

Author List

Horton TM, Drachtman RA, Chen L, Cole PD, McCarten K, Voss S, Guillerman RP, Buxton A, Howard SC, Hogan SM, Sheehan AM, López-Terrada D, Mrazek MD, Agrawal N, Wu MF, Liu H, De Alarcon PA, Trippet TM, Schwartz CL

Author

Cindy L. Schwartz MD, MPH Professor in the Pediatrics department at Medical College of Wisconsin

MESH terms used to index this publication - Major topics in bold

Adult
Antineoplastic Combined Chemotherapy Protocols
Boronic Acids
Bortezomib
Child
Child, Preschool
Disease-Free Survival
Hodgkin Disease
Humans
Ifosfamide
Neoplasm Recurrence, Local
Pyrazines
Vinblastine
Young Adult